Authors: J M Neuner T W Yen R A Sparapani P W Laud A B Nattinger
Publish Date: 2010/12/18
Volume: 22, Issue: 11, Pages: 2847-2855
Abstract
The risk of hip and other fractures was examined among a populationbased group of older women with breast cancer Women using aromatase inhibitors AIs were found to be over three times more likely to have a hip fracture over approximately 3 years’ followup Other fracture risk factors were also identifiedA populationbased cohort of 2003 breast cancer survivors ≥65 were followed prospectively for a median of 36 months Patient survey information regarding adjuvant breast cancer therapies prescription osteoporosis treatments and other factors potentially associated with fracture was supplemented with cancer registry information Hip and total nonvertebral fractures were determined using a validated Medicare algorithm and the association of these fractures with adjuvant hormonal therapies was examined using Cox modelsThe cohort of 2748 women with a mean age of 728 SD 54 included 282 who took an aromatase inhibitor and 278 tamoxifen There were 41 hip fractures 15 and 218 nonvertebral fractures 79 among the cohort Subjects using AIs adjusted hazard ratio 324 105 998 and subjects not using hormone therapy 332 114 965 were more likely than users of tamoxifen to have a hip fracture Bisphosphonate use was more common among AI users but did not explain these results Users of AIs were more likely to have nonvertebral fractures but this result did not reach statistical significance adjusted hazard 134 092 194
Keywords: